Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
When indicated, use PET-CT prior to any staging EBUS and to identify alternative biopsy target. o In cases where there is a low risk of mediastinal disease, consider percutaneous lung biopsy or proceeding directly to treatment based on lung cancer probability (including the use of the Herder model) ? Omit contrast enhanced CT brain in clinical stage II lung cancer. ? Do not perform full lung function testing when the clinician and surgeon are happy with simple spirometry. ? Do not perform (...) for SABR without nodal disease and tumours <2cm, consider SABR rather than surgery when surgical capacity is reduced. ? Consider delaying radiotherapy treatment until risk of exposure reduces in patients with stage I-II disease ? Use hypo-fractionated regimens wherever possible- See RCR emergency paper for protocols. ? Consider omitting induction component of chemoradiation and limiting to concurrent therapy. ? Consider temporarily stepping down routine post radical treatment surveillance
biomarker evaluation guideline. - TABLE 3 Recommendations on Symptom Management TABLE 4 Recommendations on Diagnosis TABLE 5 Recommendations on Staging Symptom Management Recommendations for assisting patients with symptoms of advanced colorectal cancer such as pain or bleeding are in . Discussion. More than 1.8 million patients in the world were diagnosed with colorectal cancer (CRC) in 2018. Among all patients with CRC, 20%-30% have metastatic disease from the outset (synchronous primary tumor (...) chemotherapy. , , , , In regions with fewer resource constraints, such as enhanced and maximal settings, doublet or triplet (FOLFOXIRI) chemotherapies should be available. NCCN, ESMO, and Cancer Council Australia guidelines advise that triplet chemotherapy (FOLFOXIRI) may be discussed for select patients, especially those appropriate for intensive chemotherapy, with large amount of disease burden, and when significant tumor shrinkage is the goal. , For patients treated with oxaliplatin-based chemotherapy
larotrectinib (N = 72) ? with NTRK gene fusion (n = 10) ? without NTRK gene fusion (n = 62) Subpopulations of patients with NTRK gene fusion analysed by the company: ? ePAS2 d (n = 8) ? salivary gland cancer (n = 3) ? gastrointestinal stromal cancer (n = 2) ? lung cancer - NSCLC (n = 1) ? soft tissue sarcoma (n = 1) ? thyroid cancer (n = 1) ? SAS3 e (n = 0) Data cut-off 19 February 2019: ? ESMO 2019 f (n = 12) ? separated by tumour histology: ND ? SAS3 e (n = 0) Screening: 4 weeks Treatment: until disease (...) Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Larotrectinib (solide Tumore mit einer neurotrophen Tyrosin-Rezeptor-Kinase [NTRK]-Genfusion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 January 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally
. In men, genetic factors and hormonal changes are the main factors responsible for the development of breast cancer [12-16]. Breast cancer precursors Breast cancer precursors are cell changes associated with an elevated risk of breast cancer. In addition to lesions of unclear biological potential, these precursors include ductal carcinoma in situ (DCIS), which develops within the milk ducts and has not yet grown into surrounding tissue. Due to the higher risk of it developing into malignant invasive (...) carcinoma when compared to other breast cancer precursors, surgical removal is always recommended for DCIS [13, 14, 17]. Tumour classification To describe the clinical and pathological spread of a carcinoma, it is classified on the basis of its size (T), lymph node involvement (N), and presence of distant metastases (M) (TNM classification) [14, 17, 18]. Other factors taken into account when classifying the tissue and assessing the chances for recovery include cancer tissue differentiation (grading
. Nat Rev Endocrinol. 2016;12(6):313-314. 12. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignan- cies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638-1644. 13. Yu CY, Saeed O, Goldberg AS, et al. A systematic review and me- ta-analysis of subsequent malignantneoplasm risk after radioactive iodine treatment of thyroid cancer. Thyroid. 2018;28(12):1662-1673. 14. Hill AB. The environment and disease: association or causation? 1965. J R Soc Med. 2015;108(1):32-37. 15 (...) cancer patients (mean iodine-131 activity varied from 3700 to 5500 MBq). 13 A small risk of leukaemia was observed at these doses but there was no significant increase in the occurrence of breast cancer or other solid malignancies. 13 A causative role for radioiodine in the study by Kitahara et al thus seems unlikely given that excess risk was only observed for solid malignancies in their study, and the mean administered radioiodine activity (375 MBq for Graves' disease and 488 MBq for toxic nodules
Oxodotreotide (Netspot) - adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product
C et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018; 119: 1075–1085. Colombo N, Sessa C, du Bois A et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019; 30: 672–705. Oza AM (...) eUpdate – Relapsed Epithelial Ovarian Carcinoma Treatment Recommendations Relapsed Epithelial Ovarian Carcinoma Treatment Recommendations Search eUpdate – Ovarian Cancer Treatment Recommendations eUpdate – Relapsed Epithelial Ovarian Carcinoma Treatment Recommendations Published: 01 April 2020 . Authors: ESMO Guidelines Committee Clinical Practice Guidelines This update refers to . Ledermann JA, Raja FA, Fotopoulou C et al. Ann Oncol 2013; 24 (Suppl 6): vi24–vi32. Section Chemotherapy
that specific exercise programming adaptations may be required for people with cancer based on disease and treatment-related adverse effects, anticipated disease trajectory and their health status • Effective exercise prescriptions can be delivered across a variety of settings including hospital, cancer treatment centre, community and home-based (i.e. self-managed). • Accredited exercise physiologists or physiotherapists with experience in cancer care are the most appropriate health professionals (...) and functional ability), attenuating cancer- related fatigue, alleviating psychological distress and improving quality of life across multiple general health and cancer-specific domains [3-17]. Emerging evidence highlights that regular exercise before, during and/or following cancer treatment decreases the severity of other adverse side effects and is associated with reduced risk of developing new cancers and comorbid conditions such as cardiovascular disease, diabetes and osteoporosis [3, 4]. Furthermore
. For negative margins (i.e. ink not touching invasive cancer or DCIS), thedistanceofinvasivecancerand/orDCIS from the margin(s) should be reported. No tumour at the inked margin is required and>2mm for in situ disease is preferred [63–66]. Marking the tumour bed with clips in a standardised way facili- tates accurate planning of the radiation boost if indicated. Currently achievable low local recurrence rates [ 2mm for in situ disease is preferred [I, A]. Mastectomy: Besides simple mastectomy and skin (...) - rences and improved cosmetic outcomes [II, B]. Axillary node evaluation with SLNB is not required withinsitu malignancy but may be reasonable in large and/or high-grade tumours, especially when mastectomy is required (in case an inci- dental invasive cancer is subsequently identi?ed in the surgical specimen). The risk of a positive SLN with pure DCIS is small (7%–9%) and most of the metastases found are micrometastases or isolated tumour cells, detected by IHC [82, 83]. The decision to carry out
or IB1 cervical cancer and a histological subtype of squamous-cell carcinoma, adenocarcinoma or adenosquamous carcinoma were randomly assigned to undergo minimally invasive surgery (laparoscopy or robot-assisted surgery) or conventional open surgery. Minimally invasive surgery was associated with a lower rate of disease-free survival (DFS) than open surgery [3-year rate, 91.2% versus 97.1%; hazard ratio (HR) for disease recurrence or death from cervical cancer 3.74; 95% confidence interval (CI) 1.63 (...) eUpdate – Cervical Cancer Treatment Recommendations eUpdate – Cervical Cancer Treatment Recommendations Search eUpdate – Cervical Cancer Treatment Recommendations eUpdate - Cervical Cancer Treatment Recommendations Published: 01 April 2020 . Authors: ESMO Guidelines Committee Clinical Practice Guidelines This update refers to . Section Management of local/locoregional disease; primary treatment Text update In the ESMO Clinical Practice Guidelines on cervical cancer, radical hysterectomy
EarlyCDT-Lung (Oncimmune) is a blood test that measures a group of 7 autoantibodies (p53, NYESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2) to tumour-associated antigens related to lung cancer. It helps early detection of lung cancer in people with high risk and allows differentiation of benign or malignant nodules. In the early stages of lung cancer, autoantibodies and tumour-associated antigens are produced as the body's immune system's response to cancer antigens. Blood levels of autoantibodies (...) . NICE's guideline on the diagnosis and management of lung cancer recommends sputum cytology for investigation in people with suspected lung cancer who have centrally placed nodules and are unable to tolerate bronchoscopy or invasive tests. A contrast-enhanced chest CT scan is recommended for further diagnosis and to stage the disease. The guideline recommends PET-CT as a first test after CT with a low probability of nodal malignancy (lymph nodes below 10 mm). MRI, endobronchial ultrasound-guided
University Shanghai Cancer Centre, Shanghai, China. 7 Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou, China. PMID: 32108326 DOI: Item in Clipboard Three-field Versus Two-Field Lymphadenectomy in Transthoracic Oesophagectomy for Oesophageal Squamous Cell Carcinoma: Short-Term Outcomes of a Randomized Clinical Trial B Li et al. Br J Surg . 2020 . Show details Br J Surg Actions . 2020 Feb 28. doi: 10.1002/bjs.11497. Online ahead of print. Authors (...) of Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China. 7 Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou, China. PMID: 32108326 DOI: Item in Clipboard Full-text links Cite Abstract in , Background: The benefit and harm of three-field lymphadenectomy for oesophageal cancer are still unknown. The aim of this study was to compare overall survival and morbidity and mortality between three- and two-field lymphadenectomy in patients with oesophageal squamous cell carcinoma
trial conducted at the US Department of Veterans Affairs and National Cancer Institute sites. The participants were men (n=731) ≤75yr of age with localized prostate cancer, prostate-specific antigen (PSA) <50ng/ml, life expectancy ≥10yr, and medically fit for surgery. Intervention: Radical prostatectomy versus observation. Outcome measurements and statistical analysis: All-cause mortality was assessed in the entire cohort and patient and tumor subgroups. Intention-to-treat analysis was conducted (...) with intermediate-risk disease although not in men with high-risk disease. Patient summary: In this randomized study, we evaluated death from any cause in men with early prostate cancer treated with either surgery or observation. Overall, surgery may provide small very long-term reductions in death from any cause and increases in years of life gained. Absolute effects were much smaller in men with low-risk disease, but were greater in men with intermediate-risk disease although not in men with high-risk disease
Endometrial Cancer: A Randomised Controlled Trial , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Gynaecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China. 2 Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, China. 3 Department of Clinical Epidemiology, Obstetrics and Gynaecology Hospital, Fudan University, Shanghai, China. 4 Department of Cervical Diseases, Obstetrics and Gynaecology Hospital, Fudan University (...) for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012;207:266.e1-12. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803. Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, Richard SD, Rosenblum NG, et al. Metformin